


Author's Accepted Manuscript

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies

Brandon Bumbaca, Wei Li



www.elsevier.com/locate/apsb

PII: S2211-3835(18)30134-5
DOI: <https://doi.org/10.1016/j.apsb.2018.04.007>
Reference: APSB547

To appear in: *Acta Pharmaceutica Sinica B*

Received date: 5 March 2018
Revised date: 6 April 2018
Accepted date: 26 April 2018

Cite this article as: Brandon Bumbaca and Wei Li, Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies, *Acta Pharmaceutica Sinica B*, <https://doi.org/10.1016/j.apsb.2018.04.007>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

REVIEW**Taxane Resistance in Castration-Resistant Prostate Cancer: Mechanisms and Therapeutic Strategies**

Brandon Bumbaca, Wei Li*

Department of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center, Memphis, TN, 38163

*Corresponding author

Address:

Wei Li, Ph.D., Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, 881 Madison Avenue, room 561, MEMPHIS, TN 38163, USA

Email: wli@uthsc.edu; Telephone: (901) 448-7532

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies

Brandon Bumbaca, Wei Li*

Department of Pharmaceutical Sciences, College of Pharmacy, the University of Tennessee Health Science Center, Memphis, TN 38163, USA

Received 5 March 2018; received in revised form 6 April 2018; accepted 12 April 2018

*Corresponding author. Tel.: +1 901 448 7532.

Email address: wli@uthsc.edu (Wei Li).

Running title: Taxane resistance in castration-resistant prostate cancer

Abstract Despite its good initial response and significant survival benefit in patients with castration-resistant prostate cancer (CRPC), taxane therapy inevitably encounters drug resistance in all patients. Deep understandings of taxane resistant mechanisms can significantly facilitate the development of new therapeutic strategies to

Download English Version:

<https://daneshyari.com/en/article/8507648>

Download Persian Version:

<https://daneshyari.com/article/8507648>

[Daneshyari.com](https://daneshyari.com)